Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 4Terminated 3Completed 2Active not recruiting 2

Sponsor Class

OTHER 16INDUSTRY 8NIH 3OTHER_GOV 1

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Head & Neck 3

Conditions

Melanoma 49Breast Neoplasms 47Neoplasms 39Leukemia, Lymphocytic, Chronic, B-Cell 37Carcinoma, Non-Small-Cell Lung 36Neoplasm Metastasis 29Lymphoma, Large B-Cell, Diffuse 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Brain Neoplasms 24Lymphoma, Follicular 23Lung Neoplasms 23Colonic Neoplasms 23Rectal Neoplasms 22Carcinoma, Renal Cell 22Lymphoma, Non-Hodgkin 21Prostatic Neoplasms 20Glioblastoma 20Leukemia, Myeloid, Acute 19Kidney Neoplasms 19Pancreatic Neoplasms 18Lymphoma, B-Cell, Marginal Zone 18Lymphoma, Mantle-Cell 17Gliosarcoma 17Burkitt Lymphoma 17Sarcoma 16Multiple Myeloma 16Waldenstrom Macroglobulinemia 15Ovarian Neoplasms 15Esophageal Neoplasms 15Lymphoma 14

Interventions

Platinum 1Nivolumab 1Gemcitabine 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × NIH × Nasopharyngeal Carcinoma × Clear all
NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
15 enrolled 17 charts
Head & Neck

Nasopharyngeal Carcinoma

NCT00393224 2020-06-04

Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families

National Institutes of Health Clinical Center (CC)

Terminated
952 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Neoplasms, Virus Diseases

NCT01257100 2020-06-04

Environmental and Genetic Determinants of NPC

National Institutes of Health Clinical Center (CC)

Terminated
3,500 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡